Zidovudine and HIV: Mathematical models of within‐host population dynamics

Reviews in Medical Virology

Volumn 5, Issue 3, 1995, Pages 141-147

  McLean, A R ^a,b   Frost, S D W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; NONHUMAN; REVIEW; VIRUS MUTATION;

EID: 0029552931     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1980050304     Document Type: Article

References (31)

1. Viral dynamics in human immunodeficiency virus type 1 infection
2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV‐1 infection
3. HIV population dynamics in vivo: implications for genetic variation, patho‐genesis, and therapy
4. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
5. Population dynamic of HIV within an individual after treatment with zidovudine
6. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
7. Quantitation of zidovudine‐resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients
8. Quasi‐species dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection
9. Competition between zidovudine sensitive and zidovudine resistant strains of HIV
10. Multiple mutations in HIV‐1 reverse transcriptase confer high‐level resistance to zidovudine (AZT)
11. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine
12. Susceptibility of HIV‐1 isolates to zidovudine: correlation between widely applicable culture tests and PCR analysis
13. Natural occurrence of drug resistance mutations in the reverse transcriptase of HIV type 1 isolates
14. Brief report: primary infection with zidovudine‐resistant HIV type I
15. Effects of discontinuation of zidovudine treatment on the zidovudine sensitivity of human immunodeficiency virus type I isolates
16. Resistance to ddl and sensitivity to AZT induced by mutation in HIV‐1 reverse transcriptase
17. Ordered appearance of zidovudine resistant mutations during treatment of 18 human immunodeficiency virus positive subjects
18. Is antigenic variation of HIV important for AIDS and what might be expected in the future
19. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance
20. The balance of power between HIV and the immune system
21. Germinal centre destruction as a major pathway of HIV pathogenesis
22. Antigenic diversity thresholds and the development of AIDS
23. Understanding the immune system: the role of mathematical models
24. Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS‐related complex treated with zidovudine
25. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type I (HIV) infection. A double‐blind, placebo‐controlled trial
26. Zidovudine sensitivity of human immunodeficiency viruses from high‐risk, symptom‐free individuals during therapy
27. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4‐positive cells per cubic millimeter
28. Resumption of HIV antigen production during continuous zidovudine treatment
29. The antiviral effect of zidovudine and ribavarin in clinical trials and the use of p24 antigen levels as a virological marker